Twist Bioscience (NASDAQ:TWST) entered an agreement with Lilly TuneLab, an artificial intelligence and machine learning drug discovery platform created by Eli Lilly (NYSE:LLY), to provide antibody characterization data services.
Twist Bioscience (NASDAQ:TWST) reported first-quarter fiscal 2026 results Monday that beat revenue expectations and showed significant margin improvement, as the company stays on track to reach its profitability goals by the end of the year.
Eli Lilly and Company (NYSE:LLY) filed six lawsuits against U.S. businesses accused of selling black-market retatrutide products, while the company continues efforts to report illegal sales to regulators and law enforcement.
Twist Bioscience (NASDAQ:TWST) reported financial results for its second fiscal quarter ended March 31, 2026, showcasing sustained double-digit growth across its core synthetic biology and NGS platforms.
Lilly (NYSE:LLY) signed a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, adding precision biologics programs targeting autoimmune and allergic diseases.
-640x360.webp&w=3840&q=75)
